AR056465A1 - COMPOSITIONS CONTAINING DERIVATIVES OF TAXANO - Google Patents

COMPOSITIONS CONTAINING DERIVATIVES OF TAXANO

Info

Publication number
AR056465A1
AR056465A1 ARP060103597A AR056465A1 AR 056465 A1 AR056465 A1 AR 056465A1 AR P060103597 A ARP060103597 A AR P060103597A AR 056465 A1 AR056465 A1 AR 056465A1
Authority
AR
Argentina
Prior art keywords
derivatives
taxano
ether
ester
compositions containing
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of AR056465A1 publication Critical patent/AR056465A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones basadas en derivados de taxano que comprenden una solucion de dichos derivados en un surfactante. Estas composiciones pueden ser utilizadas para preparar soluciones de perfusion. REIVINDICACION 1.- Una composicion farmacéutica adecuada para inyeccion o infusion intravenosa que comprende: - un derivado de taxano de formula (I) en donde R representa un átomo de hidrogeno o un radical acetilo y R1 representa un radical ter-butoxicarbonilamino o benzoilamino, - glicofurol como un solvente y, - un surfactante fisiologicamente aceptable seleccionado a partir del grupo consistente en cremophor, un éter o éster de polietilen glicol y un éter o éster de polioxietilen glicol.Compositions based on taxane derivatives comprising a solution of said derivatives in a surfactant. These compositions can be used to prepare perfusion solutions. CLAIM 1.- A pharmaceutical composition suitable for intravenous injection or infusion comprising: - a taxane derivative of formula (I) wherein R represents a hydrogen atom or an acetyl radical and R1 represents a tert-butoxycarbonylamino or benzoylamino radical, - glycofurol as a solvent and, - a physiologically acceptable surfactant selected from the group consisting of cremophor, an ether or ester of polyethylene glycol and an ether or ester of polyoxyethylene glycol.

ARP060103597 2005-08-19 2006-08-17 COMPOSITIONS CONTAINING DERIVATIVES OF TAXANO AR056465A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0517092A GB0517092D0 (en) 2005-08-19 2005-08-19 New compositions containing taxane derivatives

Publications (1)

Publication Number Publication Date
AR056465A1 true AR056465A1 (en) 2007-10-10

Family

ID=35098012

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103597 AR056465A1 (en) 2005-08-19 2006-08-17 COMPOSITIONS CONTAINING DERIVATIVES OF TAXANO

Country Status (3)

Country Link
AR (1) AR056465A1 (en)
GB (1) GB0517092D0 (en)
WO (1) WO2007020085A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (en) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, Related Compounds and Uses thereof
ES2383901T5 (en) 2005-02-18 2015-02-25 Angiochem Inc. Aprotinin polypeptides to transport a compound through the blood-brain barrier
ES2424242T3 (en) 2005-07-15 2013-09-30 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
WO2007134354A1 (en) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmaceutical formulation
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CN101327206B (en) * 2007-06-22 2011-07-20 成都市益斯生物科技有限公司 Docetaxel injection and preparation method thereof
AR063111A1 (en) * 2007-10-03 2008-12-30 Eriochem Sa A PHARMACEUTICAL FORMULATION OF TAXANO
KR101053780B1 (en) * 2008-02-29 2011-08-02 동아제약주식회사 Single liquid stable pharmaceutical composition containing docetaxel
WO2009111057A2 (en) 2008-03-07 2009-09-11 Scidose Llc Fulvestrant formulations
JP5860698B2 (en) * 2008-04-18 2016-02-16 アンジオケム,インコーポレーテッド Pharmaceutical compositions of paclitaxel, paclitaxel analogues or paclitaxel conjugates and related methods of preparation and use
ES2344674B1 (en) 2008-08-07 2011-06-29 Gp Pharm, S.A. INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS.
BRPI0920209A2 (en) 2008-10-15 2015-12-22 Angiochem Inc conjugates of glp-1 agonists and their uses
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (en) 2008-12-17 2011-09-27 Angiochem Inc Membrane type-1 matrix metalloprotein inhibitors and uses thereof.
ES2729261T3 (en) 2009-04-20 2019-10-31 Angiochem Inc Ovarian cancer treatment using an anticancer agent conjugated to an Angiopep-2 analog
IN2012DN00248A (en) 2009-07-02 2015-05-01 Angiochem Inc
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20120172796A1 (en) * 2010-12-30 2012-07-05 Chappa Ralph A Composition for intravascular delivery of therapeutic composition
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
ES2687705T3 (en) * 2012-07-19 2018-10-26 Fujifilm Corporation Liquid composition containing an active substance based on taxane, its production process and liquid medicinal preparation
CN104583189A (en) 2012-07-31 2015-04-29 永信药品工业股份有限公司 Amorphous cabazitaxel
WO2014028704A1 (en) * 2012-08-15 2014-02-20 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
JP6285725B2 (en) * 2014-01-16 2018-02-28 ナガセ医薬品株式会社 Ethanol-free docetaxel pharmaceutical composition
ES2826827T3 (en) 2015-06-15 2021-05-19 Angiochem Inc Methods for the treatment of leptomeningeal carcinomatosis
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2678833B1 (en) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS.
FR2698543B1 (en) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New taxoid-based compositions.
CN1209059A (en) * 1995-12-21 1999-02-24 基因实验室技术有限公司 Taxane compositions and method for producing same
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
KR20050099311A (en) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) Composition for injection comprising anticancer drug

Also Published As

Publication number Publication date
GB0517092D0 (en) 2005-09-28
WO2007020085A2 (en) 2007-02-22
WO2007020085A3 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
AR056465A1 (en) COMPOSITIONS CONTAINING DERIVATIVES OF TAXANO
GT200600518A (en) PIRIMIDINE DERIVATIVES
CY1112999T1 (en) DISEASES OF US DIVISION C
AR054790A1 (en) METHODS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
ECSP088951A (en) / STABLE PHARMACEUTICAL COMPOSITION CONTAINING DOCETAXEL AND METHOD FOR MANUFACTURING
EA200300323A1 (en) DERIVATIVES OF GUANIDININOBENZAMIDE (OPTIONS), COMPOSITION (OPTIONS), METHOD OF TREATMENT OF MEDIATED DISTRIBUTIONS mc4-r
PE20090234A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING FLORPHENICOL AND CYCLODEXTRINS
UY30493A1 (en) 5-CHLORO-1 ?? H, 3H-ESPIRO [1-BENZOFURAN-2, 4 ?? - PIPERIDIN] -1 ?? - ILO SUBSTITUTES OF ACETIC AND 2-METHYL-PROPANIC ACIDS, PHARMACEUTICAL COMPOSITIONS, PROCEDURES OF PREPARATION AND APPLICATIONS
DE602005014393D1 (en) STABLE PHARMACEUTICAL COMPOSITIONS OF ANTITUMOROUS PLATINUM (II) AGENTS
AR050918A1 (en) SOLUTION FOR INFUSION OF DIHYDROPTERIDINONES STABILIZED FOR STORAGE
CY1112831T1 (en) AZABIRENYLAMINBENZOIC ACID DERIVATIVES AS DHODH SUPPLY AGENTS
ECSP099780A (en) NEW MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
UY30819A1 (en) DERIVATIVES OF PIRAZOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
ECSP099792A (en) NEW INHIBITING PEPTIDES FOR HEPATITIS C VIRUS REPLICATION
DE60017831D1 (en) DERIVATIVE COMPOSITIONS
PE20120032A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF A DERIVATIVE OF N- [4- (8-BROMO-7-METOXYQUINOLIN-2-IL) -1,3-THIAZOL-2-IL] -2-METHYLPROPANAMIDE
MX2010003224A (en) Biaryl sulfonamide derivatives.
RU2010139958A (en) STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING DOCETSAXEL
RU2008142261A (en) PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE AND ITS APPLICATION
DE502005008631D1 (en) DERMATOLOGICAL PREPARATIONS
PT1299095E (en) AQUEOUS ANESTHESIA COMPOSITION CLEANED
UY29892A1 (en) NEW CHROMAN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
MX2007006775A (en) Stable compositions of fenofibrate with fatty acid esters.
AR056558A1 (en) METHODS TO STABILIZE OPHTHALM COMPOSITIONS
DK1377164T3 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Legal Events

Date Code Title Description
FB Suspension of granting procedure